Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Retained Earnings (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Retained Earnings for 11 consecutive years, with $32000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 107.86% to $32000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32000.0 through Dec 2025, up 107.86% year-over-year, with the annual reading at $32000.0 for FY2025, 107.86% up from the prior year.
  • Retained Earnings hit $32000.0 in Q4 2025 for Voyager Therapeutics, up from -$418.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $32000.0 in Q4 2025 to a low of -$418.5 million in Q3 2025.
  • Historically, Retained Earnings has averaged -$199.4 million across 5 years, with a median of -$276.1 million in 2023.
  • Biggest YoY gain for Retained Earnings was 107.86% in 2025; the steepest drop was 1268081.82% in 2025.
  • Year by year, Retained Earnings stood at -$347.1 million in 2021, then soared by 99.94% to -$219000.0 in 2022, then tumbled by 119161.19% to -$261.2 million in 2023, then skyrocketed by 99.84% to -$407000.0 in 2024, then surged by 107.86% to $32000.0 in 2025.
  • Business Quant data shows Retained Earnings for VYGR at $32000.0 in Q4 2025, -$418.5 million in Q3 2025, and -$390.6 million in Q2 2025.